$NRIX
Nurix Therapeutics, Inc.

2021 Q1 Form 10-K Financial Statement

#000156459021006071 Filed on February 16, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q4 2020 Q3
Revenue $5.011M $6.689M $4.085M
YoY Change 74.97% 259.24% -61.39%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.530M $6.250M $4.340M
YoY Change 166.53% 140.38% 99.08%
% of Gross Profit
Research & Development $23.00M $20.45M $18.94M
YoY Change 77.4% 59.52% 72.05%
% of Gross Profit
Depreciation & Amortization $640.0K $640.0K $550.0K
YoY Change 30.61% 18.52% -1.79%
% of Gross Profit
Operating Expenses $29.53M $26.70M $23.28M
YoY Change 91.56% 73.04% 111.46%
Operating Profit -$24.52M
YoY Change 95.35%
Interest Expense $320.0K $140.0K $680.0K
YoY Change 88.24% -46.15% 240.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$24.20M -$19.87M -$18.52M
YoY Change 95.51% 49.29% 666.12%
Income Tax $71.00K $40.00K $0.00
% Of Pretax Income
Net Earnings -$24.28M -$19.91M -$18.52M
YoY Change 95.91% 47.3% 662.96%
Net Earnings / Revenue -484.43% -297.71% -453.29%
Basic Earnings Per Share -$1.09
Diluted Earnings Per Share -$626.1K -$1.920M -$1.09
COMMON SHARES
Basic Shares Outstanding 38.91M 38.86M 16.94M
Diluted Shares Outstanding 16.94M

Balance Sheet

Concept 2021 Q1 2020 Q4 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $303.1M $281.0M $354.1M
YoY Change 325.7%
Cash & Equivalents $126.4M $119.4M $265.5M
Short-Term Investments $176.7M $161.8M $88.70M
Other Short-Term Assets $3.700M $6.100M $6.200M
YoY Change -32.73%
Inventory
Prepaid Expenses
Receivables $7.500M
Other Receivables $3.800M
Total Short-Term Assets $310.8M $298.4M $364.1M
YoY Change 305.17% 658.33%
LONG-TERM ASSETS
Property, Plant & Equipment $6.960M $6.672M $6.532M
YoY Change 74.0% 72.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $77.20M $90.90M $40.90M
YoY Change 915.79%
Other Assets $1.571M $177.0K $185.0K
YoY Change 161.83% 20.41%
Total Long-Term Assets $85.89M $97.91M $47.79M
YoY Change 609.85% 1985.83%
TOTAL ASSETS
Total Short-Term Assets $310.8M $298.4M $364.1M
Total Long-Term Assets $85.89M $97.91M $47.79M
Total Assets $396.7M $396.3M $411.9M
YoY Change 346.69% 799.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.388M $3.412M $3.611M
YoY Change 108.95% 113.52%
Accrued Expenses $10.80M $8.300M $7.100M
YoY Change 66.15%
Deferred Revenue $32.75M $32.80M $30.30M
YoY Change 241.23%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $47.97M $44.54M $41.01M
YoY Change 59.91% 176.01%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $832.0K $850.0K $868.0K
YoY Change -98.97% -51.07%
Total Long-Term Liabilities $832.0K $850.0K $868.0K
YoY Change -98.97% -51.07%
TOTAL LIABILITIES
Total Short-Term Liabilities $47.97M $44.54M $41.01M
Total Long-Term Liabilities $832.0K $850.0K $868.0K
Total Liabilities $126.5M $106.1M $104.3M
YoY Change 14.61% 98.02%
SHAREHOLDERS EQUITY
Retained Earnings -$128.0M -$103.7M -$83.78M
YoY Change 71.53%
Common Stock $398.1M $393.9M $391.3M
YoY Change 14254.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $270.1M $290.3M $307.6M
YoY Change
Total Liabilities & Shareholders Equity $396.7M $396.3M $411.9M
YoY Change 346.69% 799.8%

Cashflow Statement

Concept 2021 Q1 2020 Q4 2020 Q3
OPERATING ACTIVITIES
Net Income -$24.28M -$19.91M -$18.52M
YoY Change 95.91% 47.3% 662.96%
Depreciation, Depletion And Amortization $640.0K $640.0K $550.0K
YoY Change 30.61% 18.52% -1.79%
Cash From Operating Activities $8.053M -$20.48M -$6.140M
YoY Change -80.35% 60.63% -116.88%
INVESTING ACTIVITIES
Capital Expenditures $843.0K -$900.0K -$1.670M
YoY Change 131.59% -5.26% 240.82%
Acquisitions
YoY Change
Other Investing Activities -$1.540M -$123.7M -$106.4M
YoY Change -91.92% 3526.39% -2760.25%
Cash From Investing Activities -$2.387M -$124.6M -$108.1M
YoY Change -87.71% 2756.88% -3188.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.359M -1.130M 220.4M
YoY Change 2854.35% -1512.5%
NET CHANGE
Cash From Operating Activities 8.053M -20.48M -6.140M
Cash From Investing Activities -2.387M -124.6M -108.1M
Cash From Financing Activities 1.359M -1.130M 220.4M
Net Change In Cash 7.025M -146.2M 106.2M
YoY Change -67.47% 758.31% 166.37%
FREE CASH FLOW
Cash From Operating Activities $8.053M -$20.48M -$6.140M
Capital Expenditures $843.0K -$900.0K -$1.670M
Free Cash Flow $7.210M -$19.58M -$4.470M
YoY Change -82.24% 65.93% -112.13%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
119356000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
161792000
CY2020Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
7500000
CY2020Q4 us-gaap Income Tax Receivable
IncomeTaxReceivable
3846000
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3871000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
170000
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
170000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
177000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
147000
CY2019Q4 us-gaap Assets
Assets
44048000
CY2020Q4 us-gaap Assets
Assets
396343000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3412000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1598000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2740000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-60456000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-57714000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
44048000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1634000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
39354000
CY2019Q4 us-gaap Long Term Investments
LongTermInvestments
506000
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2020 dei Entity File Number
EntityFileNumber
001-39398
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-0838048
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
1700 Owens Street
CY2020 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 205
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
San Francisco
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94158
CY2020 dei City Area Code
CityAreaCode
415
CY2020 dei Local Phone Number
LocalPhoneNumber
660-5320
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
38907223
CY2020Q3 dei Entity Public Float
EntityPublicFloat
452000000
CY2020 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2020 dei Trading Symbol
TradingSymbol
NRIX
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34816000
CY2019Q4 us-gaap Short Term Investments
ShortTermInvestments
2904000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5940000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
298434000
CY2020Q4 us-gaap Long Term Investments
LongTermInvestments
90890000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6672000
CY2020Q4 nrix Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
8328000
CY2019Q4 nrix Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
4927000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
9612000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16137000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
60685000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
850000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1737000
CY2019Q4 us-gaap Liabilities
Liabilities
53567000
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
48195000
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
39000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
393841000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
87000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-103698000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
290269000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
396343000
CY2020Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0
CY2019Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
48441667
CY2020Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2019Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
12813887
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2019Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
12813887
CY2020Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
0
CY2019Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
48383000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-20535000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-43242000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-21699000
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-6.59
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0034
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
239000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
119526000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34986000
CY2020 us-gaap Operating Expenses
OperatingExpenses
82803000
CY2019 us-gaap Operating Expenses
OperatingExpenses
53351000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-22236000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2020 nrix Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
129000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4301000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
65000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38864872
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3595334
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38864872
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3595334
CY2020 us-gaap Revenues
Revenues
17820000
CY2019 us-gaap Revenues
Revenues
31115000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
66494000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45025000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16309000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8326000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-64983000
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.76
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15673424
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3292514
CY2020 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
0
CY2019 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
28400000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
89000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-43153000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21697000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-36847000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
104000
CY2019 nrix Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
216000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
510000
CY2019 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
2000
CY2020 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
168109000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
218147000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
450000
CY2020 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
89000
CY2020 us-gaap Profit Loss
ProfitLoss
-43242000
CY2019 us-gaap Profit Loss
ProfitLoss
-21699000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2180000
CY2019 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2354000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
4301000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
510000
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-273000
CY2019 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
109000
CY2020 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
7500000
CY2020 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
3846000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3941000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
15000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1234000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
302000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
48179000
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
16885000
CY2020 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
2282000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2157000
CY2020 nrix Conversion Of Redeemable Convertible Preferred Stock Into Common Stock Upon Closing Of Initial Public Offering
ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockUponClosingOfInitialPublicOffering
168109000
CY2019 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
2373000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-80000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
601000
CY2020 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
275224000
CY2019 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
9351000
CY2020 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
25373000
CY2019 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
19500000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4553000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1651000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-254404000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
8498000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
218147000
CY2020 us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
119914000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
970000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
142000
CY2020 nrix Payments For Repurchase Of Unvested Early Exercised Stock Options
PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions
7000
CY2019 nrix Payments For Repurchase Of Unvested Early Exercised Stock Options
PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions
16000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
339024000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
126000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
84540000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9225000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
34986000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
25761000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
119526000
CY2020 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1000
CY2019 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
580000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
152000
CY2020 nrix Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
129000
CY2019 nrix Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
216000
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to the useful lives of long-lived assets, the measurement of stock-based compensation, accruals for research and development activities, income taxes and revenue recognition. The Company bases its estimates on historical experience and on other relevant assumptions that are reasonable under the circumstances. Actual results could materially differ from those estimates. </p>
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents and investments. The Company&#8217;s investments consist of debt securities issued by highly rated corporate entities, the U.S. federal government or state and local governments. The Company&#8217;s exposure to any individual corporate entity is limited by policy. Deposits may, at times, exceed federally insured limits, but minimal credit risk exists. The Company invests its cash equivalents in highly rated money market funds. The Company has not experienced any credit losses on its deposits of cash and cash equivalents. </p>
CY2019 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8153546
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
15139883
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1554594
CY2020Q4 nrix Working Capital
WorkingCapital
253900000
CY2020Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.333
CY2020 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-3
CY2020 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
CY2020 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2019 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0
CY2019Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0
CY2019 nrix Proceeds From Milestone Payments
ProceedsFromMilestonePayments
0
CY2019 nrix Milestone Revenues Recognized
MilestoneRevenuesRecognized
0
CY2019 nrix Substantive Milestones
SubstantiveMilestones
0
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
19855000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
14874000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
13183000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11003000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5725000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3751000
CY2020Q4 nrix Accrued Contract Research And Lab Supplies
AccruedContractResearchAndLabSupplies
1238000
CY2019Q4 nrix Accrued Contract Research And Lab Supplies
AccruedContractResearchAndLabSupplies
322000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
591000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
512000
CY2020Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
74000
CY2019Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
33000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
700000
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
309000
CY2020Q4 nrix Transfers Of Financial Instruments Between Valuation Levels
TransfersOfFinancialInstrumentsBetweenValuationLevels
0
CY2019Q4 nrix Transfers Of Financial Instruments Between Valuation Levels
TransfersOfFinancialInstrumentsBetweenValuationLevels
0
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
CY2020 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0
CY2019 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0
CY2020 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
0
CY2015Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P60M
CY2020Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P14M
CY2017Q4 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2025-04-30
CY2020Q2 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2021-07-31
CY2020 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
In November 2017, the Company entered into an amendment to its original lease agreement that combined the Company’s two leases into a single lease agreement and extended the term of the lease agreement through April 30, 2025
CY2020Q4 us-gaap Security Deposit
SecurityDeposit
91000
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
3023000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3400000
CY2019 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2616000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
3272000
CY2019 us-gaap Operating Lease Expense
OperatingLeaseExpense
2927000
CY2019 us-gaap Operating Leases Rent Expense Sublease Rentals1
OperatingLeasesRentExpenseSubleaseRentals1
311000
CY2020 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
3023000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
3365000
CY2020Q4 nrix Share Based Compensation Arrangement By Share Based Payment Award Options Shares Subject To Repurchase
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesSubjectToRepurchase
141512
CY2020Q4 nrix Share Based Compensation Arrangements By Share Based Payment Award Options Exercise Value Of Shares Subject To Repurchase
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExerciseValueOfSharesSubjectToRepurchase
500000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
3438000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
3541000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1493000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
15109000
CY2020 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one
CY2020 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.50
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.41
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
3100000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
500000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.73
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
2295000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
9330000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
137000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
6941000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.11
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.79
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.16
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0142
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0179
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0255
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
26800000
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y6M
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
400000
CY2019 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
300000
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-20500000
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
200000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-63777000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-21460000
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-20577000
CY2019 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
238000
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
42000
CY2019 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1000
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.062
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.102
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.040
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.066
CY2020 nrix Effective Income Tax Rate Reconciliation Unrecognized Income Tax Benefits
EffectiveIncomeTaxRateReconciliationUnrecognizedIncomeTaxBenefits
0.006
CY2019 nrix Effective Income Tax Rate Reconciliation Unrecognized Income Tax Benefits
EffectiveIncomeTaxRateReconciliationUnrecognizedIncomeTaxBenefits
-0.010
CY2020 nrix Effective Income Tax Rate Reconciliation Federal Rate Impact Due To Cares Act
EffectiveIncomeTaxRateReconciliationFederalRateImpactDueToCARESAct
0.131
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.103
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.370
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.024
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.009
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.322
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.011
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
25145000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
31533000
CY2020Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
10536000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
773000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
37000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
1624000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
1260000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
47408000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
39771000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
47408000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
39763000
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
8000
CY2019Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
8000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
8000
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
8500000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
7600000
CY2020Q4 nrix Net Operating Loss Unutilized Amount
NetOperatingLossUnutilizedAmount
400000
CY2020Q4 us-gaap Decrease In Unrecognized Tax Benefits Is Reasonably Possible
DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
1500000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
5361000
CY2020Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2920000
CY2020 nrix Percentage Of Net Operating Loss Carryover And Carryback Offset Of Taxable Income Cares Act
PercentageOfNetOperatingLossCarryoverAndCarrybackOffsetOfTaxableIncomeCARESAct
1.00
CY2019Q4 us-gaap Revenues
Revenues
1862000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-2685000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-3068000
CY2020 nrix Income Tax Decrease In Tax Credits Research Amount
IncomeTaxDecreaseInTaxCreditsResearchAmount
1000000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-2427000
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-13519000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1326000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
626000
CY2020 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
1180000
CY2019Q3 us-gaap Revenues
Revenues
10580000
CY2020 nrix Net Operating Loss Carryback Period Cares Act
NetOperatingLossCarrybackPeriodCARESAct
P5Y
CY2020Q2 nrix Net Operating Loss Carryback Refund Claim Cares Act
NetOperatingLossCarrybackRefundClaimCARESAct
15700000
CY2020Q2 nrix Net Operating Loss Carryback Refund Claim Additional Amount Of Income Tax Cares Act
NetOperatingLossCarrybackRefundClaimAdditionalAmountOfIncomeTaxCARESAct
3900000
CY2020Q3 nrix Income Taxes Refund Received On First Refund Claim Cares Act
IncomeTaxesRefundReceivedOnFirstRefundClaimCARESAct
16300000
CY2020Q3 nrix Income Interest Received Cares Act
IncomeInterestReceivedCARESAct
600000
CY2020Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
3900000
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4589886
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14867072
CY2020Q1 us-gaap Revenues
Revenues
2864000
CY2020Q2 us-gaap Revenues
Revenues
4182000
CY2020Q3 us-gaap Revenues
Revenues
4085000
CY2020Q4 us-gaap Revenues
Revenues
6689000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-12391000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
7580000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-18517000
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-19914000
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3539390
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3731838
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
16937934
CY2020Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38702486
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.50
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
2.03
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.09
CY2020Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
CY2019Q1 us-gaap Revenues
Revenues
9234000
CY2019Q2 us-gaap Revenues
Revenues
9439000
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3195047
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3433080
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3667335
CY2019Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3812210
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.84
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.89
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.66
CY2019Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.55
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
8052905
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.90

Files In Submission

Name View Source Status
0001564590-21-006071-index-headers.html Edgar Link pending
0001564590-21-006071-index.html Edgar Link pending
0001564590-21-006071.txt Edgar Link pending
0001564590-21-006071-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gyclq5tgybt2000001.jpg Edgar Link pending
gyclq5tgybt2000002.jpg Edgar Link pending
gyclq5tgybt2000003.jpg Edgar Link pending
gyclq5tgybt2000004.jpg Edgar Link pending
gyclq5tgybt2000005.jpg Edgar Link pending
gyclq5tgybt2000006.jpg Edgar Link pending
gyclq5tgybt2000007.jpg Edgar Link pending
gyclq5tgybt2000008.jpg Edgar Link pending
gyclq5tgybt2000009.jpg Edgar Link pending
gyclq5tgybt2000010.jpg Edgar Link pending
gyclq5tgybt2000011.jpg Edgar Link pending
gyclq5tgybt2000012.jpg Edgar Link pending
gyclq5tgybt2000013.jpg Edgar Link pending
gyclq5tgybt2000014.jpg Edgar Link pending
gyclq5tgybt2000015.jpg Edgar Link pending
gyclq5tgybt2000016.jpg Edgar Link pending
gyclq5tgybt2000017.jpg Edgar Link pending
gyclq5tgybt2000018.jpg Edgar Link pending
gyclq5tgybt2000019.jpg Edgar Link pending
gyclq5tgybt2000020.jpg Edgar Link pending
gyclq5tgybt2000021.jpg Edgar Link pending
gyclq5tgybt2000022.jpg Edgar Link pending
nrix-10k_20201130.htm Edgar Link pending
nrix-20201130.xml Edgar Link completed
nrix-20201130.xsd Edgar Link pending
nrix-20201130_cal.xml Edgar Link unprocessable
nrix-20201130_def.xml Edgar Link unprocessable
nrix-20201130_lab.xml Edgar Link unprocessable
nrix-20201130_pre.xml Edgar Link unprocessable
nrix-ex1011_158.htm Edgar Link pending
nrix-ex107_389.htm Edgar Link pending
nrix-ex211_157.htm Edgar Link pending
nrix-ex231_159.htm Edgar Link pending
nrix-ex311_156.htm Edgar Link pending
nrix-ex312_155.htm Edgar Link pending
nrix-ex321_154.htm Edgar Link pending
nrix-ex43_153.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending